Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Bone Therapeutics SA
  6. News
  7. Summary
    BOTHE   BE0974280126

BONE THERAPEUTICS SA

(BOTHE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Bone Therapeutics and Link Health Signs Non-Binding Term Sheet for the Global Rights of ALLOB

11/29/2021 | 01:00am EST

BONE THERAPEUTICS and Link Health Pharma Co. Ltd. announced the signing of a non-binding term sheet for the global rights for ALLOB, Bone Therapeutics? allogeneic bone cell therapy. Subject to the fulfillment of customary condition precedents, Bone Therapeutics and Link Health aim to complete the final agreement and to fully execute it by the end of 2021. This new partnership is separate and independent from the existing license agreement signed on October 5, 2020, for the rights to develop, manufacture and commercialize ALLOB in China for Pregene, and in Hong Kong, Macau, Singapore, Taiwan, Thailand and South Korea for Link Health. Bone Therapeutics will continue to work closely in partnership with Link Health and Pregene on all development activities. Link Health will be responsible for all future development, including the ongoing ALLOB TF2 Phase IIb trial and costs related to development, process development (scale up) and manufacturing of ALLOB. The deal will have no immediate direct cash impact, other than support of all development costs, since no upfront payment is foreseen, however, Bone Therapeutics will receive commercial milestone payments of up to ?60 million in total and tiered royalties on net sales of up to 25%.


ę S&P Capital IQ 2021
All news about BONE THERAPEUTICS SA
01/19Bone Therapeutics provides fourth quarter 2021 business update and 2022 outlook
AQ
2021BONE THERAPEUTICS - Transparency notification received from S.R.I.W. SA and Sofipole SA..
AQ
2021BONE THERAPEUTICS SA : Transparency notification received from S.R.I.W. SA and Sofipôle SA
AQ
2021BONE THERAPEUTICS SA : Crossing thresholds
CO
2021Nyenburgh Raises Bone Therapeutics Stake to Almost 6%
MT
2021BONE THERAPEUTICS SA : Transparency notification received from Nyenburgh Holding NV
AQ
2021BONE THERAPEUTICS SA : Monthly statement on outstanding equity shares and voting rights
CO
2021BONE THERAPEUTICS SA : Monthly statement on outstanding equity shares and voting rights
CO
2021Bone Therapeutics Raises $4 Million To Advance Lead Orthopedic Asset
MT
2021Bone Therapeutics announces closing of private placement
AQ
More news
Analyst Recommendations on BONE THERAPEUTICS SA
More recommendations
Financials
Sales 2021 20,8 M 23,5 M 23,5 M
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 12,3 M 13,9 M 13,9 M
Capi. / Sales 2021 0,59x
Capi. / Sales 2022 4,56x
Nbr of Employees 30
Free-Float 82,2%
Chart BONE THERAPEUTICS SA
Duration : Period :
Bone Therapeutics SA Technical Analysis Chart | BOTHE | BE0974280126 | MarketScreener
Technical analysis trends BONE THERAPEUTICS SA
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,58 €
Average target price 2,50 €
Spread / Average Target 333%
Managers and Directors
Miguel Forte Chief Executive Officer & Director
Lieve Creten Chief Financial Officer
Baron Jean StÚphenne Chairman
Anthony Ting Chief Scientific Officer
Anne Leselbaum Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BONE THERAPEUTICS SA-13.21%14
JOHNSON & JOHNSON-4.73%429 034
ROCHE HOLDING AG-9.06%304 714
PFIZER, INC.-12.72%289 287
ABBVIE INC.-2.39%233 643
ELI LILLY AND COMPANY-12.00%217 963